Abstract 846TiP
Background
Survival benefits from clinical trials have established continuous BTKi as standard of care (SOC) in CLL/SLL; however, median duration of continuous BTKi in a real-world setting is short (ibrutinib: 16.5 months in FIRE study), undermining its survival benefits. BTKi plus chemoimmunotherapy or BCL-2 inhibitor, as new time-limited combination, has shown high response rates and good long-term prognosis in CLL, but whether fixed-duration (FD) regimen surpasses continuous BTKi is unclear, especially in a real-world setting. To provide more effective treatment option and clinical guidance, we perform a prospective, phase II trial with wider inclusion criteria and closer representation for real-world clinical practice, comparing FD orelabrutinib (O) plus widely used bendamustine (B) and rituximab (R) in China (called OBR) with continuous BTKi in treatment-naïve CLL/SLL. We also explore the duration of undetectable minimal residual disease (uMRD), rate of MRD negativity, and their correlation with efficacy of FD OBR.
Trial design
Adult CLL/SLL patients requiring initial therapy per iwCLL 2018 criteria and ECOG performance status of 0-2 are eligible. Patients will be enrolled from 6 centers in China and receive either FD OBR (treatment group, n=40) or SOC (continuous BTKi until outgroup; control group, n=20) in a 28-day cycle. B (70 mg/m2 on days 1-2 each cycle) and R (375 mg/m2 on day 1 of cycle 1 and then 500 mg/m2 of cycles 2-4) are dosing for up to 4 cycles. O (150 mg daily) is given from cycle 2 to cycle 18, followed by treatment extension (maximum duration of 23 cycles throughout the study) or treatment-free observation per clinical judgment and patient preference. Study spans from May 2024 to May 2027. Primary endpoint is to compare the percentage of patients who initiated a next treatment at 30 months or die between two groups; secondary endpoints include between-group comparisons for progression-free survival, time to treatment failure, objective response rate, complete response rate, and safety; and 15-month patient compliance in control group.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
202P - eIF4E inhibition exhibits anti-tumor activity and re-sensitizes acquired resistant KRAS G12C NSCLC to KRAS inhibitors
Presenter: Andrew Truong
Session: Poster session 09
203P - An innovative evidence-based laboratory medicine (EBLM) test to help doctors in multi-cancer early detection (MCED)
Presenter: Jose D Santotoribio
Session: Poster session 09
204P - Assessing biomarker testing awareness among patients and caregivers in NSCLC through an interdisciplinary global survey
Presenter: Rodrigo Paredes
Session: Poster session 09
205P - Detection and diagnosis of lung cancer by electronic nose analysis of exhaled breath: A multi-center prospective observational study
Presenter: Alessandra Buma
Session: Poster session 09
206P - Unveiling the link: How metabolic syndrome drives endometrial cancer progression
Presenter: Lirong Zhai
Session: Poster session 09
Resources:
Abstract
207P - Associations of diabetic background retinopathy and ER+ breast cancer risk: A Mendelian randomization study
Presenter: Shu Wang
Session: Poster session 09
208P - Role of plasma exosomes in crosstalk between immune system and hereditary ovarian cancer: Opportunity or challenge?
Presenter: Daniele Fanale
Session: Poster session 09
209P - A novel method for early evaluation of drug-specific predictive biomarker
Presenter: Gal Dinstag
Session: Poster session 09
210P - Therapeutic implications of phosphoproteomics in molecular cancer diagnostics
Presenter: Annika Schneider
Session: Poster session 09
211P - GynePDX: A new platform of preclinical models for endometrial and ovarian cancers
Presenter: Melek Denizli
Session: Poster session 09